EADV Urticaria 2012

During the XXI Conference of the European Academy of Dermatology and Venereology (EADV Conference), a satellite symposium was held on bilastine, a new, second-generation non-sedating H1 antihistamine recently approved for the second-generation of allergic rhinoconjunctivitis and urticaria in the 28 countries of the European Union (EU).

Only registered health professionals are allowed to see the report

Login